TTrialPathMatch Me to Trials
← Back to trials
RecruitingCOVID -19COVID - 19COVID 19

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Eligible age

18–79 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine

You may qualify if…

  • ✓ 1. 18-79 years old
  • ✓ 2. Have a history of any of the following risk factors for severe COVID:
  • ✓ Current:
  • ✓ Age \> 65 years old
  • ✓ Physical inactivity (defined as \<150 mins of moderate activity per week or \<75 mins of vigorous activity per week)
  • ✓ HIV with CD4 count ≥ 500 cells/ul
  • ✓ Smoker
  • ✓ Obesity with BMI ≥ 30 and \< 40

You may not qualify if…

  • ✕ 1. History of severe allergy or severe adverse reaction such as myocardial inflammation to any component of the mRNA COVID-19 vaccines or the Novavax recombinant COVID-19 vaccine
  • ✕ 2. Received a COVID-19 vaccine in the last 3 months.
  • ✕ 3. Tested positive for COVID-19 in the past 3 months.
  • ✕ \- Presence of fever, cough, chills, shortness of breath, runny nose, or sore throat today on day of screening/enrollment visit.
  • ✕ 4. Active use of immune modulating medications.
  • ✕ \- Defined as active use of chronic immune modulating medications such as systemic corticosteroids at a dose equivalence of 20 mg prednisone or greater daily for over one month, chemotherapy, cytokine inhibitors, or agents that reduce T cell or B cell numbers or function.
  • ✕ 5. Diagnosed with immunocompromised stated.
  • ✕ \- Defined as: presence of a disease that is actively causing severe immune suppression or history of prior splenectomy (removal of spleen).

Where it's recruiting

Maryland

Bethesda

Source: ClinicalTrials.gov · NCT07287137 · last updated 2026-11-02

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study · TrialPath